Skip to main content

Table 5 Reports of adverse reactions determined by abnormal laboratory data

From: A laboratory data-based evaluation of the efficacy and safety of generic pravastatin sodium for long-term use

Age (years)

Sex

Treatment duration (weeks)

Adverse reaction

CTCAE Grade

70

Female

16

Increased CPK

200

IU/L

I

66

Female

10

Increased CPK

219

IU/L

I

67

Female

40

Increased CPK

189

IU/L

I

68

Female

15

Increased CPK

200

IU/L

I

78

Female

4

Increased CPK

2898

IU/L

IV

52

Male

12

Increased CPK

321

IU/L

I

67

Male

35

Increased CPK

762

IU/L

I

36

Male

4

Increased CPK

404

IU/L

I

40

Male

10

Increased CPK

815

IU/L

II

69

Female

4

Increased AST

49

IU/L

I

41

Male

32

Increased ALT

42

IU/L

I

Increased ALP

376

IU/L

I

Increased γ-GTP

194

IU/L

II

65

Male

23

Decreased Hb

9.7

g/dL

-

85

Female

15

Thrombocytopenia

65,000

/mL

II

  1. Aspartate aminotransferase, AST; alanine aminotransferase, ALT; creatine phosphokinase, CPK; gamma-glutamyl transferase, γGTP; alkaline phosphatase, ALP; hemoglobin, Hb; The Common Terminology Criteria for Adverse Events, CTCAE